CoChat
Sign Up
Cited by 64

The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.

Fecal microbiota transplantation as a new therapy: from Clostridioides difficile infection to inflammatory bowel disease, irritable bowel syndrome, and colon cancer

Borody, Thomas J, Eslick, Guy D, Clancy, Robert L·2019·Current Opinion in Pharmacology
DOI 10.1016/j.coph.2019.04.017
Open this paper in CoChat — free account

Abstract

Fecal microbiota transplantation (FMT) represents the most effective means of therapeutically manipulating the gastrointestinal microbiome. Originally employed as a treatment of last-resort in patients with life-threatening Clostridioides difficile infection (CDI), FMT gained widespread acceptance during the CDI epidemic, where it achieved resolution rates approaching 100%. Following our newfound appreciation for the role of the gut microbiome in both health and disease and owing to FMT's unique mechanism/s of action, FMT is rapidly advancing as an effective treatment for a number of conditions in which the gastrointestinal microbiome is thought to play a role. We review the role of FMT from its beginnings in CDI to its expansion into inflammatory bowel disease, irritable bowel syndrome, and colon cancer.

Overview

Integrity signals

Registry

Crossref · 10.1016/j.coph.2019.04.017

Cites

11 of 11 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

1 retracted

Flagged first, then by citations

Show all 11 references

Research works printed but not linked: 49

  1. Eiseman, 1958, Fecal enema as an adjunct in the treatment of pseudomembranous enterocolitis, Surgery, 44, 854
  2. Lawson, 2016, Reclassification of Clostridium difficile as clostridioides difficile (Hall and O’Toole 1935) Prévot 1938, Anaerobe, 40, 95, 10.1016/j.anaerobe.2016.06.008 · DOI
  3. O’Connor, 2009, Clostridium difficile infection caused by the epidemic BI/NAP1/027 strain, Gastroenterology, 136, 1913, 10.1053/j.gastro.2009.02.073 · DOI
  4. Zuo, 2018, Bacteriophage transfer during faecal microbiota transplantation in Clostridium difficile infection is associated with treatment outcome, Gut, 67, 634, 10.1136/gutjnl-2017-313952 · DOI
  5. Zuo, 2018, Gut fungal dysbiosis correlates with reduced efficacy of fecal microbiota transplantation in Clostridium difficile infection, Nat Commun, 9, 10.1038/s41467-018-06103-6 · DOI
  6. Sartor, 2017, Roles for intestinal bacteria, viruses, and fungi in pathogenesis of inflammatory bowel diseases and therapeutic approaches, Gastroenterology, 152, 327, 10.1053/j.gastro.2016.10.012 · DOI · Paper page
  7. Bowden, 1981, Pseudomembranous enterocolitis: mechanism for restoring floral homeostasis, Am Surg, 47, 178
  8. Schwan, 1983, Relapsing Clostridium difficile enterocolitis cured by rectal infusion of homologous faeces, Lancet, 2, 845, 10.1016/S0140-6736(83)90753-5 · DOI
  9. Costello, 2019, Effect of fecal microbiota transplantation on 8-week remission in patients with ulcerative colitis, JAMA, 321, 156, 10.1001/jama.2018.20046 · DOI
  10. Ianiro, 2017, Predictors of failure after single faecal microbiota transplantation in patients with recurrent Clostridium difficile infection: results from a 3-year, single-centre cohort study, Clin Microbiol Infect, 23, 337.e1, 10.1016/j.cmi.2016.12.025 · DOI
  11. Khan, 2018, Comparing fecal microbiota transplantation to standard-of-care treatment for recurrent Clostridium difficile infection: a systematic review and meta-analysis, Eur J Gastroenterol Hepatol, 1309, 10.1097/MEG.0000000000001243 · DOI
  12. Youngster, 2017, Making fecal microbiota transplantation easier to swallow: freeze-dried preparation for recurrent Clostridium difficile infections, Am J Gastroenterol, 112, 948, 10.1038/ajg.2017.91 · DOI
  13. Staley, 2017, Successful resolution of recurrent Clostridium difficile infection using freeze-dried, encapsulated fecal microbiota; pragmatic cohort study, Am J Gastroenterol, 112, 940, 10.1038/ajg.2017.6 · DOI
  14. Staley, 2017, Community dynamics drive punctuated engraftment of the fecal microbiome following transplantation using freeze-dried, encapsulated fecal microbiota, Gut Microbes, 8, 276, 10.1080/19490976.2017.1299310 · DOI
  15. Rao, 2017, Capsules for fecal microbiota transplantation in recurrent Clostridium difficile infection: the new way forward or a tough pill to swallow?, JAMA, 318, 1979, 10.1001/jama.2017.17969 · DOI
  16. Jiang, 2017, Randomised clinical trial: faecal microbiota transplantation for recurrent Clostridum difficile infection-fresh, or frozen, or lyophilised microbiota from a small pool of healthy donors delivered by colonoscopy, Aliment Pharmacol Ther, 45, 899, 10.1111/apt.13969 · DOI
  17. Kao, 2017, Effect of oral capsule- vs colonoscopy-delivered fecal microbiota transplantation on recurrent Clostridium difficile infection: a randomized clinical trial, JAMA, 318, 1985, 10.1001/jama.2017.17077 · DOI · Paper page
  18. Hocquart, 2018, Early fecal microbiota transplantation improves survival in severe Clostridium difficile infections, Clin Infect Dis, 66, 645, 10.1093/cid/cix762 · DOI
  19. Hoffmann, 2017, Improving regulation of microbiota transplants, Science, 358, 1390, 10.1126/science.aaq0034 · DOI
  20. Hoffmann, 2017, A proposed definition of microbiota transplantation for regulatory purposes, Gut Microbes, 8, 208, 10.1080/19490976.2017.1293223 · DOI
  21. Ma, 2017, Ethical issues in fecal microbiota transplantation in practice, Am J Bioethics, 17, 34, 10.1080/15265161.2017.1299240 · DOI
  22. Ma, 2017, How Chinese clinicians face ethical and social challenges in fecal microbiota transplantation: a questionnaire study, BMC Med Ethics, 18, 39, 10.1186/s12910-017-0200-2 · DOI
  23. Kelly, 2017, The AGA’s fecal microbiota transplantation national registry: an important step toward understanding risks and benefits of microbiota therapeutics, Gastroenterology, 152, 681, 10.1053/j.gastro.2017.01.028 · DOI
  24. Browne, 2017, Fecal transplant in inflammatory bowel disease, Gastroenterol Clin N Am, 46, 825, 10.1016/j.gtc.2017.08.005 · DOI
  25. Ye, 2015, The epidemiology and risk factors of inflammatory bowel disease, Int J Clin Exp Med, 8, 22529
  26. Galazzo, 2019, Fecal microbiota dynamics and its relation with disease course in Crohn’s disease, J Crohns Colitis, 10.1093/ecco-jcc/jjz049 · DOI
  27. Fuentes, 2017, Microbial shifts and signatures of long-term remission in ulcerative colitis after faecal microbiota transplantation, ISME J, 11, 1877, 10.1038/ismej.2017.44 · DOI
  28. Dinakaran, 2019, Identification of specific oral and gut pathogens in full thickness colon of colitis patients: implications for colon motility, Front Microbiol, 9, 3220, 10.3389/fmicb.2018.03220 · DOI
  29. Meighani, 2017, Outcomes of fecal microbiota transplantation for Clostridium difficile infection in patients with inflammatory bowel disease, Dig Dis Sci, 62, 2870, 10.1007/s10620-017-4580-4 · DOI
  30. Khanna, 2017, Changes in microbial ecology after fecal microbiota transplantation for recurrent C. difficile infection affected by underlying inflammatory bowel disease, Microbiome, 5, 55, 10.1186/s40168-017-0269-3 · DOI
  31. Narula, 2017, Systematic review and meta-analysis: fecal microbiota transplantation for treatment of active ulcerative colitis, Inflamm Bowel Dis, 23, 1702, 10.1097/MIB.0000000000001228 · DOI
  32. Costello, 2017, Systematic review with meta-analysis: faecal microbiota transplantation for the induction of remission for active ulcerative colitis, Aliment Pharmacol Ther, 46, 213, 10.1111/apt.14173 · DOI
  33. Qazi, 2017, The risk of inflammatory bowel disease flares after fecal microbiota transplantation: systematic review and meta-analysis, Gut Microbes, 8, 574, 10.1080/19490976.2017.1353848 · DOI
  34. Khanna, 2017, Management of Clostridium difficile infection in inflammatory bowel disease: expert review from the clinical practice updates committee of the AGA Institute, Clin Gastroenterol Hepatol, 15, 166, 10.1016/j.cgh.2016.10.024 · DOI
  35. Xu, 2019, Efficacy of fecal microbiota transplantation in irritable bowel syndrome: a systematic review and meta-analysis, Am J Gastroenterol, 10.14309/ajg.0000000000000198 · DOI
  36. El-Salhy, 2018, Fecal microbiota transplantation for managing irritable bowel syndrome, Expert Rev Gastroenterol Hepatol, 12, 439, 10.1080/17474124.2018.1447380 · DOI
  37. Burkitt, 1972, Classics in oncology. A sarcoma involving the jaws in African children, CA Cancer J Clin, 22, 345
  38. Eslick, 1999, Association of helicobacter pylori infection with gastric carcinoma: a meta-analysis, Am J Gastroenterol, 94, 2373, 10.1111/j.1572-0241.1999.01360.x · DOI
  39. Chang, 1994, Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi’s sarcoma, Science, 266, 1865, 10.1126/science.7997879 · DOI
  40. Howley, 2015, Gordon Wilson lecture: infectious disease causes of cancer: opportunities for prevention and treatment, Trans Am Clin Climatol Assoc, 126, 117
  41. Keusch, 1974, Opportunistic infections in colon carcinoma, Am J Clin Nutr, 27, 1481, 10.1093/ajcn/27.12.1481 · DOI
  42. Krishnan, 2014, Streptococcus bovis infection and colorectal neoplasia: a meta-analysis, Colorectal Dis, 16, 672, 10.1111/codi.12662 · DOI
  43. Wassenaar, 2018, E. coli and colorectal cancer: a complex relationship that deserves a critical mindset, Crit Rev Microbiol, 44, 619, 10.1080/1040841X.2018.1481013 · DOI
  44. Shang, 2018, Fusobacterium nucleatum and colorectal cancer: a review, World J Gastrointest Oncol, 10, 71, 10.4251/wjgo.v10.i3.71 · DOI · Paper page
  45. Boleij, 2015, The Bacteroides fragilis toxin gene is prevalent in the colon mucosa of colorectal cancer patients, Clin Infect Dis, 60, 208, 10.1093/cid/ciu787 · DOI · Paper page
  46. Xu, 2017, Analysis of mucosa-associated microbiota in colorectal cancer, Med Sci Monit, 23, 4422, 10.12659/MSM.904220 · DOI
  47. Duvallet, 2017, Meta-analysis of gut microbiome studies identifies disease-specific and shared responses, Nat Commun, 8, 10.1038/s41467-017-01973-8 · DOI
  48. Kang, 2017, Microbiome and colorectal cancer: unravelling host-microbiota interactions in colitis-associated colorectal cancer development, Semin Immunol, 32, 3, 10.1016/j.smim.2017.04.003 · DOI
  49. Yu, 2018, Impact of microbiota in colorectal carcinogenesis: lessons from experimental models, Intest Res, 16, 346, 10.5217/ir.2018.16.3.346 · DOI

Cited by

Sorted by citations

See all 64

Metadata

Authors
Borody, T. J., Eslick, G. D., & Clancy, R. L.
Venue
Current Opinion in Pharmacology
Publisher
Elsevier BV
Published
2019-12
Volume
49
Pages
43-51
ISSN
1471-4892
DOI
10.1016/j.coph.2019.04.017
Cited by
64
References
11
Language
en
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review